ENGENE HOLDINGS INC (ENGN) Stock News

NASDAQ:ENGN - CA29286M1059 - Common Stock

4.87 USD

+0.07 (+1.46%)

Last: 9/3/2025, 4:30:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENGN Latest News, Press Relases and Analysis

All

Press Releases

11 hours ago - By: enGene Holdings Inc.

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

6 days ago - By: Benzinga - Mentions: IVA BOLT RLMD CMND ...

12 Health Care Stocks Moving In Thursday's After-Market Session

7 days ago - By: enGene Holdings Inc.

enGene to Participate in Upcoming Investor Conferences

a month ago - By: enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10 months ago - By: Benzinga

Why enGene Holdings Stock Is Trading Higher

2 months ago - By: enGene Holdings Inc.

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

2 months ago - By: enGene Holdings Inc.

FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

3 months ago - By: enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3 months ago - By: enGene Holdings Inc.

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: enGene Holdings Inc.

enGene Announces the Resignation of its Chief Medical Officer

3 months ago - By: enGene Holdings Inc.

enGene to Present at the Jefferies Global Healthcare Conference

3 months ago - By: enGene Holdings Inc.

enGene Names Amy Pott as Chief Global Commercialization Officer

4 months ago - By: enGene Holdings Inc.

enGene to Participate in Upcoming Investor Conferences

4 months ago - By: Yahoo Finance - Mentions: DHI CMG

Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?

5 months ago - By: enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

5 months ago - By: enGene Holdings Inc.

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

6 months ago - By: enGene Holdings Inc.

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: enGene Holdings Inc.

enGene to Participate in the Leerink Partners Global Healthcare Conference

7 months ago - By: enGene Holdings Inc.

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

7 months ago - By: enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

7 months ago - By: enGene Holdings Inc.

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

8 months ago - By: enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

9 months ago - By: enGene Holdings Inc.

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

9 months ago - By: enGene Holdings Inc.

enGene to Participate in Upcoming Investor Conferences

10 months ago - By: enGene Holdings Inc.

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

10 months ago - By: enGene Holdings Inc.

enGene Announces $60 Million Private Placement Financing

11 months ago - By: enGene Holdings Inc.

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

11 months ago - By: enGene Holdings Inc.

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

a year ago - By: enGene Holdings Inc.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

a year ago - By: enGene Holdings Inc.

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

a year ago - By: enGene Holdings Inc.

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

a year ago - By: enGene Holdings Inc.

enGene to Participate in Upcoming Investor Conferences